The following full text is a publisher's version.

For additional information about this publication click this link.
http://hdl.handle.net/2066/155117

Please be advised that this information was generated on 2019-04-02 and may be subject to change.
Effect of *IKZF1* deletions on signal transduction pathways in Philadelphia chromosome negative pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL)

Naomi E van der Sligte¹, Frank J G Scherpen¹, Arja ter Elst¹, Victor Guryev², Frank N van Leeuwen³ and Eveline S J M de Bont¹*

Abstract

**Background:** *IKZF1* deletions are an unfavorable prognostic factor in children with Philadelphia chromosome positive (Ph⁺) as well as negative (Ph⁻) acute lymphoblastic leukemia (ALL). Although *IKZF1* deletions occur in 10–15% of Ph⁻ ALL cases, effects of *IKZF1* deletions on signaling pathways in this group have not been extensively studied. Therefore, in this study we aimed to study the effect of *IKZF1* deletions on active signal transduction pathways.

**Methods:** Multiplex ligation-dependent probe amplification (MLPA) was used to determine *IKZF1* deletions and other copy number alterations in 109 pediatric B-Cell Precursor ALL (BCP-ALL) patients. Kinase activity profiling of 45 primary Ph⁻ BCP-ALL patients (31 *IKZF1* wild type patients and 14 patients harboring an *IKZF1* alteration) and western blot analysis of 14 pediatric BCP-ALL samples was performed to determine active signal transduction pathways.

**Results:** Unsupervised hierarchical cluster analysis of kinome profiles of 45 pediatric Ph⁻ ALL cases showed no clustering based on *IKZF1* status. Comparing the phosphorylation intensities of peptides associated with signaling pathways known to be involved in BCP-ALL maintenance, we did not observe differences between the two groups. Western blot analysis of 14 pediatric BCP-ALL samples showed large variations in phosphorylation levels between the different ALL samples, independent of *IKZF1* status.

**Conclusions:** Based on these results we conclude that, although *IKZF1* deletions appear to be an important clinical prognostic factor, we were unable to identify a unique *IKZF1* dependent protein expression signature in pediatric Ph⁻ ALL and consequently no specific targets for future therapy of Ph⁻ *IKZF1* deleted BCP-ALL could be identified.

**Keywords:** Acute lymphoblastic leukemia, *IKZF1*, Signaling, Kinome profiling

Background

Overall survival rates for children with Acute Lymphoblastic Leukemia (ALL), the most common type of cancer in children, are approaching 90% [1]. Historically, risk stratification of newly diagnosed children was based on age and white blood cell count (WBC), but nowadays includes extensive cytogenetic and molecular analyses. In the past 5 years, genome wide approaches, studying DNA copy number alterations in ALL, have identified novel molecular markers that can be used for further risk stratification, including *IKZF1* deletions as a predictor of poor outcome. *IKZF1* deletions can be identified in approximately 70% of the children with Philadelphia chromosome positive (Ph⁺) ALL and in 10–15% of the children with Philadelphia chromosome negative (Ph⁻) ALL and are associated with an increased relapse risk and decreased overall survival in both groups [2–4]. More recent studies indicate that the genomic context

---

*Correspondence: E.S.J.M.de.Bont@umcg.nl
¹ Division of Pediatric Oncology/Hematology, Department of Pediatrics, Beatrix Children’s Hospital, University Medical Center Groningen, University of Groningen, PO Box 30.001, 9700 RB Groningen, The Netherlands
Full list of author information is available at the end of the article

© 2015 van der Sligte et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
in which IKZF1 deletions occur is more important for prognosis as for example CRLF2 and JAK2 mutations are more common in IKZF1 deleted BCP-ALL [5–7]. In pediatric B-cell progenitor ALL (BCP-ALL), 80% of the IKZF1 deletions are found in a Philadelphia chromosome negative background.

IKZF1, which encodes the transcription factor Ikaros, is essential for normal lymphoid development, whereas for erythroid and myeloid lineage differentiation IKZF1 is less critical [8]. Mice deficient for IKZF1 show a complete arrest in B-lymphocyte development while mice heterozygous for a dominant-negative mutation of IKZF1 develop T cell leukemia and lymphoma with a 100% penetrance [9, 10]. During normal development, Ikaros restricts the G1-S transition of the cell cycle when it binds to the DNA, by regulating transcription of cell cycle regulator genes e.g. a positive effect on cell cycle inhibitors CDKN1A (p21Cip1) and CDKN1B (p27Kip1) [11]. Phosphorylation of Ikaros by casein kinase II (CK2) temporarily reduces Ikaros binding to DNA and thereby facilitates progression through the S phase of the cell cycle [11]. Furthermore, Ikaros can be phosphorylated by spleen tyrosine kinase (SYK) and bruton's tyrosine kinase (BTK) [12, 13]. These phosphorylation events are essential for nuclear localization, regulation of DNA binding activity, and an optimal transcriptional function of Ikaros [12, 13].

IKZF1 deletions observed in BCP-ALL are typically mono-allelic, either resulting in a loss of function or the expression of a dominant-negative isoform [14]. The dominant-negative isoforms lack the DNA binding N-terminal zinc fingers, preventing DNA binding after dimerization with Ikaros [15]. As a result, the control of Ikaros on the G1-S transition is abolished leading to hyperproliferation and the development of leukemia [11]. Although the cure rates for children with BCP-ALL have improved substantially, the outcome after ALL relapse remains poor. Since IKZF1 deletions increase the risk of relapse, new therapeutic options aiming to improve cure rates for this specific subtype of ALL are needed. We have previously shown that insight into active signal transduction pathways allows identification of interesting targets for future therapy [16–19]. At the level of signal transduction, Iacobucci et al. showed on western blot analysis a higher STAT5 phosphorylation in IKZF1 deleted compared to IKZF1 wild type adult BCP-ALL patients with unknown cytogenetic background [20]. However, this observation might also be associated with BCR-ABL1 activity as in adult BCP-ALL patients IKZF1 deletions are more common in Ph+ ALL [21]. Additionally, Ikaros-reconstitution in two IKZF1 deleted Philadelphia positive ALL patients resulted in an upregulation of the B-cell receptor (BCR) signaling pathway and a concomitant cell cycle arrest; showing that in Ph+ ALL pre-B cell receptor signaling suppresses proliferation through an Ikaros-mediated cell cycle arrest [22]. Although IKZF1 deletions in children are most commonly found in a Philadelphia negative background, the effect of IKZF1 deletions on signaling pathways in Philadelphia negative ALL have not been extensively studied. Therefore, in this study we aimed to study the effect of IKZF1 deletions on active signal transduction pathways in Philadelphia negative pediatric BCP-ALL using kinome profiling.

**Methods**

**Patients**

Primary blood and bone marrow samples from newly diagnosed ALL patients were collected after getting written informed consent in accordance with the regulations and protocols of the medical ethics committee of the University Medical Center Groningen. Overall, we collected material of 109 Philadelphia negative BCP-ALL patients. Mononuclear cells were isolated by Lymphoprep (Nycomed, Zürich, Switzerland) density gradients and cryopreserved in liquid nitrogen until use. The cryopreserved leukemia cells were thawed rapidly at 37°C and diluted in a 6 ml volume of newborn calf serum, as described earlier [23].

**DNA isolation**

Genomic DNA was extracted from mononuclear cells using the QiAamp DNA easy kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. All isolated DNA was quantified by NanoDrop spectrophotometry (NanoDrop, Wilmington, DE, USA).

**Multiplex ligation-dependent probe amplification (MLPA)**

Targeted copy number screening of eight selected loci was performed in the cohort by multiplex ligation-dependent probe amplification (MLPA) using the P335-B2 SALSA MLPA kit (MRC-Holland, Amsterdam, The Netherlands). The assay includes probes for each of the eight exons of the IKZF1 gene and is able to detect deletions of the whole gene as well as all types of focal intragenic deletions. Selected exons of the genes BTG1, CDKN2A/B, EBF1, ETV6, PAX5, RB1 and the PAR1 region (approx. 230 kbp downstream of SHOX, CRLF2, CSF2RA and IL3RA) are also covered. Probe mix and hybridization buffer (MRC-Holland) were added in equal amounts to 50 ng of genomic DNA followed by heat denaturation and overnight hybridization of the probes at 60°C. Subsequently, ligation was performed and the ligation products were amplified by PCR using a 6-FAM fluorophore-labeled primer set (MRC-Holland). The amplification products were quantified and identified by capillary electrophoresis on an ABI 3730 DNA analyzer (Applied Biosystems, Foster City, CA, USA).
Data analysis: Data were analyzed using GeneMapper v.4.0 software (Applied Biosystems). Normalization of the data was carried out by dividing the peak area of each probe by the average peak area of the control probes. This normalized peak pattern was divided by the average peak pattern of all the samples in the same experiment. The resulting values were 1 for every wild-type peak, peak pattern of all the samples in the same experiment. The microarray contain 1,024 peptides in triplicate (1,008 unique target peptides and 16 peptides used for production) derived from known phosphorylation sites from human protein sequences that can be phosphorylated by the kinases in the sample lysate. For sample, 0.5 × 10^6 cells were lysed in 100 µl of M-PER Mammalian Protein Extraction Buffer containing 1 µl Phosphatase Inhibitor and 1 µl Protease Inhibitor (Pierce, Rockford, IL, United States). Peptide array incubation mix was produced by adding 10 µl of filter-cleared activation mix onto 90 µl cell lysate. Peptide array incubation mix was loaded on the chip and incubated for 2 h at 37°C in a closed humid box at saturated humidity. Subsequently, the peptide array was washed and blow dried with compressed air or N2 and the chips were exposed to a phospho-storage box at saturated humidity. Subsequently, the peptide chip and incubated for 2 h at 37°C in a closed humid box at saturated humidity. Subsequently, the peptide chip was washed and blow dried with compressed air or N2 and the chips were exposed to a phospho-storage box at saturated humidity. Subsequently, the peptide chip and incubated for 2 h at 37°C in a closed humid box at saturated humidity. Subsequently, the peptide chip and incubated for 2 h at 37°C in a closed humid box at saturated humidity. Subsequently, the peptide chip and incubated for 2 h at 37°C in a closed humid box at saturated humidity. Subsequently, the peptide chip and incubated for 2 h at 37°C in a closed humid box at saturated humidity. Subsequently, the peptide chip and incubated for 2 h at 37°C in a closed humid box at saturated humidity.

Data analysis: Data were analyzed as described previously [18, 19]. In short, background was subtracted and the spot intensities were quantile normalized. A Pearson's correlation coefficient was determined over the triplicates (Excel 2003, Microsoft Office, Redmond, WA, United States). Slides with a correlation <0.6 over the triplicates were excluded from further analysis. The correlation over the triplicates was <0.6 in none of the samples. Cluster, statistical and heatmap analysis were performed using Qlucore Omics Explorer 3.0 (Qlucor AB, Lund, Sweden). The file containing the processed raw data can be found in the additional information (Additional file 1: Table S1).

Western blot analysis
Primary ALL cells were solved in laemmli sample buffer (Bio-Rad laboratories, Veenendaal, the Netherlands). Proteins were separated by sodium dodecyl sulphate–polyacrylamide gel electrophoresis, and transported to nitrocellulose membranes. Membranes were blocked in 7.5% skimmed milk and incubated overnight with primary antibodies for phospho-Src_Y416, phospho-Syk_Y323, phospho-ERK1/2_T202/Y204, phospho-CREB_S133, phospho-p38_T180/Y182, phospho-Akt_S473, phospho-mTOR_S2448, phospho-GSK3β/α_S21/S9, phospho-MDM2_S166, phospho-Chk2_T68, phospho-RB1_S807/811, phospho-STAT3_Y705, phospho-STAT5_Y694 (Cell Signaling, Danvers, MA, USA), or phospho-p27_T187 (Abgent, San Diego, CA, United States) and for 1 h with HRP conjugated secondary antibodies (Dako, Glostrup, Denmark). Protein bands were visualized using the ChemiDoc MP imaging system (Bio-Rad, Hercules, CA, United States) and ImageLab software (version 5.0, Bio-Rad Laboratories). Loading control was visualized using β-actin (Santa Cruz Biotechnology, Dallas, TX, United States).

Results
Generation of kinase activity profiles in IKZF1 deleted versus IKZF1 wild type Philadelphia negative pediatric BCP-ALL
MLPA analysis revealed that among the 109 Philadelphia negative pediatric BCP-ALL patients tested, 17 (15.6%) patients harbor an IKZF1 deletion whereas one patient (0.9%) showed a gain of IKZF1. We generated kinase activity profiles of 31 IKZF1 wild type patients and 14 patients with an IKZF1 alteration (13 patients with an IKZF1 deletion and 1 patient with a gain of IKZF1). No material was available for kinome profiling of the other three patients with an IKZF1 deletion. Among the 14 patients harboring an IKZF1 alteration, deletions in exons 1 through 8 (4 patients, 28.6%), 4 through 7 (3 patients, 21.4%), and 4 through 8 (3 patients, 21.4%) were most frequent (Fig. 1). Patients' characteristics are shown in Fig. 1. Patients harboring an IKZF1 alteration appeared to be older compared to IKZF1 wild type patients (8.4 versus 5.7 years, respectively, P = 0.038). Furthermore, MLPA analysis showed more CSF2RA alterations in the group with IKZF1 alterations compared to the IKZF1 wild type group (P = 0.003).

Kinase activity profiles were generated to reveal potential differences in signaling between IKZF1 deleted and non-deleted Ph− pediatric BCP-ALL cases. Compared to previously performed kinome arrays, we observed a good variability in peptide phosphorylation intensities among the 1,008 unique target peptides and within the 45 individual patients, indicating that the experimental conditions were optimal. Unsupervised hierarchical cluster analysis showed no clustering based upon IKZF1 status (Fig. 2a). Moreover, no differential clustering could be observed based on karyotype and copy number alterations of PAX5, ETV6, CDKN2A, CDKN2B, and CRLF2.

PepChip
Kinase activity profiles of 45 primary Ph− BCP-ALL patients were determined using the PepChip Kinomics microarray system (Pepsan, Lelystad, the Netherlands) and performed as described previously [18, 19]. The microarray contain 1,024 peptides in triplicate (1,008 unique target peptides and 16 peptides used for production) derived from known phosphorylation sites from human protein sequences that can be phosphorylated by the kinases in the sample lysate. Per sample, 0.5 × 10^6 cells were lysed in 100 µl of M-PER Mammalian Protein Extraction Buffer containing 1 µl Phosphatase Inhibitor and 1 µl Protease Inhibitor (Pierce, Rockford, IL, United States). Peptide array incubation mix was produced by adding 10 µl of filter-cleared activation mix onto 90 µl cell lysate. Peptide array incubation mix was loaded on the chip and incubated for 2 h at 37°C in a closed humid box at saturated humidity. Subsequently, the peptide array was washed and blow dried with compressed air or N2 and the chips were exposed to a phospho-storage screen for 24–96 h. The amount of bound ^32P-labelled ATP to the peptides specifies the amount of peptide phosphorylation and was analyzed with array software (ScanAlyze, Eisen Lab, University of California at Berkeley, Berkely, CA, United States).
The clustering in peptide activity was not correlated to patients’ characteristics as age, gender, and white blood cell count (WBC) at diagnosis (Additional file 2: Figure S1). To evaluate whether \textit{IKZF1} deletions display a unique kinase signature we studied differences in peptide phosphorylation intensities by \textit{t}-test analysis. Thirty-eight peptides were differentially phosphorylated between \textit{IKZF1} deleted (\(N = 13\)) and \textit{IKZF1} wild type (\(N = 31\)) pediatric Ph\(^-\) BCP-ALL patients: phosphorylation of 14 peptides was higher in the \textit{IKZF1} deleted group and 24 peptides showed reduced phosphorylation intensities (\(P \leq 0.05\), Fig. 2b, Additional file 3: Table S2). In Fig. 2b, normalized peptide intensities are shown with each variable normalized to mean 0 and variance 1. Although we observed thirty-eight peptides to be differentially phosphorylated, absolute differences of normalized peptide phosphorylation intensities between \textit{IKZF1} deleted and wild type samples were small (Additional file 4: Figure S2; Additional file 3: Table S2). Focusing on the normalized peptide phosphorylation intensities, high phosphorylation levels of peptides derived from Cytohesin-1\_S394 and Cytohesin-2\_S392 were shown. The list of top 100 most highly phosphorylated peptides also showed only subtle variations between \textit{IKZF1} deleted and wild type cases (Additional file 5: Table S3). Although no gross differences in peptide phosphorylation levels were observed, the list of top 100 highest phosphorylated peptides included a number of potentially druggable targets for the treatment of BCP-ALL. Among the top 100 most highly phosphorylated peptides, we identified 86 peptides...
Fig. 2  Kinome profile in Philadelphia chromosome negative pediatric BCP-ALL patients. 

a: Unsupervised hierarchical clustering of 45 pediatric BCP-ALL cases; 13 IKZF1 deleted, 1 IKZF1 gain, and 31 IKZF1 wild type Philadelphia chromosome negative patients based on 1,008 unique target peptides. No distinct clustering could be observed based on IKZF1 status, neither on genetic background or other copy number alterations. 

b: Unsupervised hierarchical clustering of 44 pediatric BCP-ALL cases; 13 IKZF1 deleted and 31 IKZF1 wild type patients based on 38 differentially phosphorylated peptides identified by t test. Each row represents a peptide, each column represents a single ALL sample. The magnitude of deviation from the median is represented by the color saturation with each variable normalized to mean 0 and variance 1. Red and green spots display the phosphorylation intensity above and below the median, respectively.
previously defined as activated peptides in pediatric ALL including cAMP responsive element binding protein 1 (CREB1), peptides derived from protein kinases related to the PI3K/Akt-signaling pathway including peptides related to phosphatidylinositol 3 kinases and ribosomal S6 kinases, and peptides derived from regulators of the cell cycle including checkpoint kinase 2 and retinoblastoma 1 [19].

Signal transduction pathway activation in response to IKZF1 status
To focus more closely on active signal transduction pathways, we determined peptide phosphorylation of proteins involved in important signaling pathways for BCP-ALL cell proliferation and survival (e.g. the BCR signaling pathway, the MAPK, PI3K/Akt/mTOR, JAK/STAT5 signaling pathways), adhesion pathways, and regulators of the cell cycle (including p21Cip1 and p27Kip1, Fig. 3). Activity of these signaling pathways could be observed in both IKZF1 wild type and IKZF1 deleted pediatric Ph− ALL patients. Comparing phosphorylation intensities of peptides associated with these main signaling pathways showed no differences in pathway activation between IKZF1 wild type and IKZF1 deleted Ph− ALL (Additional file 6: Table S4).
Phosphorylation levels of key signaling proteins in *IKZF1* deleted and wild type BCP-ALL

Previously, upregulation of the B-cell receptor (BCR) signaling pathway was reported in adult Ph⁺ ALL in response to Ikaros-reconstitution, as well as an increased STAT5 phosphorylation in *IKZF1* deleted versus wild type adult ALL cases with unknown cytogenetic background [20, 22]. Although various peptides involved in the BCR signaling pathway and peptides derived from STAT5 were present on the array, we did not observe these differences in our Ph⁻ cases. Therefore, in addition to the kinase profiles, we performed western blot analysis of 14 pediatric BCP-ALL samples; seven Philadelphia negative *IKZF1* wild type patients, six Philadelphia negative *IKZF1* deleted patients, and one Philadelphia positive *IKZF1* deleted patient (Fig. 4). The western blot results showed a large variation in phosphorylation levels between the different ALL samples. STAT5_Y694 phosphorylation could be detected in the Philadelphia positive patient (patient no 14) and in two Philadelphia negative patients with an *IKZF1* deletion (patients no 6 and 8), but was not detectable in the other *IKZF1* deleted Philadelphia negative patients (patients no 7, 9, 10, and 13, Fig. 4). The western blot results showed that protein phosphorylation of Src_Y416, Syk_Y323, ERK1/2_T202/Y204, CREB_S133, p38_T180/Y182, Akt_S473, mTOR_S2448, GSK3α/β_S21/S9, MDM2_S166, p27_T187, Chk2_T68, Rb1_S807/811, and STAT3_Y705 was clearly independent of *IKZF1* status. Neither did we observe a clear relation between the western blot results and known copy number alterations of *PAX5*, *ETV6*, *Rb1*, *CDKN2A*, *CDKN2B*, or *CRLF2* (Fig. 4). In conclusion, our kinase and western blot results suggest that *IKZF1* deletions do not predict a unique protein expression signature in pediatric Ph⁻ ALL.

**Discussion**

*IKZF1* deletions are found in approximately 70% of the children with Philadelphia chromosome positive (Ph⁺) ALL and in 10–15% of the children with Philadelphia chromosome negative (Ph⁻) ALL. In both groups, *IKZF1* deletions are associated with an increased risk on relapse and decreased overall survival [2–4]. In Ph⁻ ALL, the effect of *IKZF1* deletions on outcome is most pronounced in children with an intermediate treatment response based on the minimal residual disease at days 42 and 84 [24]. Although multiple studies have established *IKZF1* as a prognostic factor in pediatric BCP-ALL, the effect of *IKZF1* deletions on signaling pathways in Philadelphia negative B-cell precursor ALL is poorly understood. In previous studies, we have shown that kinase profiling can be used successfully to describe active signal transduction pathways in pediatric malignancies [16–19]. In this study we used kinome profiling to elucidate the effect of *IKZF1* deletions on active signal transduction pathways.

Unexpectedly, unsupervised hierarchical cluster analysis revealed no clustering between *IKZF1* deleted and wild type patients. Furthermore, peptide phosphorylation intensities between *IKZF1* deleted and wild type Ph⁻ BCP-ALL patients were very comparable as shown by the phosphorylation intensities of the thirty-eight differentially phosphorylated peptides and by the list of top 100 most highly phosphorylated peptides. While focusing on important signaling pathways involved in cell proliferation and survival of BCP-ALL cells we showed activity of all these pathways, however, no differences between the *IKZF1* deleted versus the *IKZF1* wild type group could be observed. Moreover, western blots of several key proteins involved in ALL signaling showed a variety of phosphorylation events, clearly unrelated to *IKZF1* status.

Although no clear differences in peptide phosphorylation intensities could be observed, kinase profiles showed a remarkable high phosphorylation of peptides derived from Cytohesin-1_S394 and Cytohesin-2_S392. Cytohesins have been described as ErbB receptor activators [25]. It has been described that Cytohesin overexpression enhances epidermal growth factor receptor (EGFR) signaling in human cancers including lung cancer and colorectal cancer [25, 26]. Although kinase domain mutations of ErbB receptors are uncommon in acute leukemias, in vitro inhibition of ErbB2 reduces cell proliferation especially when combined with BCR-ABL tyrosine kinase inhibitors in Ph⁺ ALL, suggesting a role for ErbB signaling pathway activation in leukemia [27, 28]. Therefore, it will be interesting to further explore the role of Cytohesin in BCP-ALL.

Although we did not identify a unique kinase signature as a result of *IKZF1* status, effects of *IKZF1* deletions on gene expression were described previously. Iacobucci et al. showed that *IKZF1* deletions display a unique gene expression signature in a cohort of adult B-ALL patients, including patients with a Philadelphia translocation and B-ALL patients negative for known molecular rearrangements [20]. The gene expression signature was characterized by the downregulation of genes regulating B-cell lineage development and DNA repair upon DNA damage response genes and upregulation of cell cycle/apoptosis genes, JAK/STAT signaling and stem cell self-renewal [20]. More recently, besides an upregulation of genes associated with B-cell proliferation, an upregulation of genes involved in cell adhesion and communication was also observed in pediatric Ph⁻ ALL [29].

In addition to a unique *IKZF1* dependent gene expression profile, a subtype of precursor BCP-ALL with a similar gene expression profile compared to
Philadelphia-positive ALL was identified several years ago (Ph-like ALL) [2, 30]. Importantly, 68% of the patients with Ph-like ALL showed deletions in \textit{IKZF1} [31]. Within the Ph-like ALL subtype, 5-year event-free survival rates in patients with \textit{IKZF1} alterations were inferior compared to Ph-like \textit{IKZF1} wild type ALL patients [31]. Recently, Roberts et al. defined the genomic landscape of Ph-like ALL in a large cohort of children and adolescents to elucidate kinase-activating genetic alterations which might include potential leads for targeted therapy [31]. Genomic alterations activating kinase signaling were identified in 91% of the Ph-like ALL patients (\(N = 156\)) including ABL-class fusions, rearrangements of \textit{JAK2} or \textit{CRLF2}, genetic alterations including \textit{IL7R} and \textit{FLT3}, and Ras pathway mutations [31]. Patients harboring \textit{IKZF1} alterations (\(N = 96, 61.5\%\)) were distributed over all groups of different kinase alterations, indicating a high degree of heterogeneity within the group of \textit{IKZF1} deleted patients [31]. Our results and the results of Roberts et al. suggest that patients harboring \textit{IKZF1} alterations represent a
heterogeneous subgroup when evaluated at the level of active signal transduction pathways. The identification of potential targets for tyrosine kinase inhibitors therefore appears to be dictated by upstream genomic alterations that activate kinase signaling or cytokine receptor pathways rather than IKZF1 status per se.

Conclusions
The aim of this study was to elucidate the effect of IKZF1 deletions on active signal transduction pathways using kinase profiling and western blot analysis in children with Ph⁻ BCP-ALL. Although IKZF1 deletions are an important clinical prognostic factor we were unable to identify a unique IKZF1 associated protein expression signature in pediatric Ph⁻ BCP-ALL and consequently no specific targets for future therapy of Ph⁻ IKZF1 deleted BCP-ALL were identified.

Additional files

Additional file 1: Table S1. Data file containing processed raw data values of the PepChip.

Additional file 2: Figure S1. Supplementary unsupervised hierarchical clustering. Kinase activity profiles of 45 pediatric BCP-ALL patients were generated. Unsupervised hierarchical clustering of 1,008 unique target peptides using Quicore Omics Explorer 3.0 showed no distinct clustering based on the patients’ characteristics age, gender and white blood cell count (WBC).

Additional file 3: Table S2. List of 38 differentially phosphorylated peptides. Thirty-eight peptides were differentially phosphorylated between IKZF1 deleted (N = 13) and IKZF1 wild type (N = 31) Philadelphia negative pediatric BCP-ALL patients as determined by t-test analysis. The phosphorylation of 14 peptides was higher in the IKZF1 deleted group and 24 peptides showed reduced phosphorylation intensities. Shown are the normalized peptide phosphorylation intensities as well as P values.

Additional file 4: Figure S2. Absolute phosphorylation intensities of 38 differentially phosphorylated peptides. Supervised hierarchical clustering of 44 pediatric BCP-ALL cases, 13 IKZF1 deleted and 31 IKZF1 wild type Philadelphia chromosome negative patients based on 38 peptides identified by t-test. Each row represents a peptide, each column represents a single ALL sample. Absolute phosphorylation intensities are shown by the color saturation, red and green spots display high and low phosphorylation intensities, respectively.

Additional file 5: Table S3. Top 100 most highly phosphorylated peptides. Shown is the list of top 100 highest phosphorylated peptides in IKZF1 deleted and IKZF1 wild type Philadelphia negative pediatric BCP-ALL patients. Highlighted peptides are overlapping peptides between IKZF1 deleted and IKZF1 wild type.

Additional file 6: Table S4. List of proteins involved in important signaling pathways for BCP-ALL. Shown are proteins involved in important signaling pathways for BCP-ALL cell proliferation and survival (e.g. the BCR signaling pathway, the MAPK, PI3 K/Akt/mTOR, JAK/STAT5 signaling pathways), adhesion pathways, and regulators of the cell cycle (including p21Cip1 and p27Kip1). The mean normalized phosphorylation intensities of multiple peptides derived from indicated proteins as well as P-values are shown for IKZF1 deleted (N = 13) and IKZF1 wild type (N = 31) pediatric patients.

Abbreviations
ALL: acute lymphoblastic leukemia; BCP-ALL: B-cell progenitor acute lymphoblastic leukemia; BCR: B-cell receptor; BTK: Bruton’s tyrosine kinase; CK2: casein kinase II; MLPA: multiplex ligation-dependent probe amplification; Ph⁻: Philadelphia chromosome negative; Ph⁺: Philadelphia chromosome positive; SYK: spleen tyrosine kinase.

Authors’ contributions
NExDS performed research, collected data, analyzed data and wrote the paper. FJGS performed research and collected data. ME supervised pepchip data analysis. VG performed quantile normalization and supervised pepchip data analysis. FvNL supervised and edited the paper. ESJMdB designed research, analyzed data, supervised and edited the paper. All authors read and approved the final manuscript.

Author details
1 Division of Pediatric Oncology/Hematology, Department of Pediatrics, Beatrix Children’s Hospital, University Medical Center Groningen, University of Groningen, PO Box 30.001, 9700 RB Groningen, The Netherlands. 2 European Research Institute for the Biology of Ageing, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. 3 Laboratory of Pediatric Oncology, Department of Pediatrics, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.

Acknowledgements
We thank the Junior Scientific Masterclass, University of Groningen, Groningen, The Netherlands for financial support.

Compliance with ethical guidelines
Competing interests
The authors declare that they have no competing interests.

Received: 24 July 2015 Accepted: 27 July 2015
Published online: 12 August 2015

References


